Health News Roundup: Polio Resurgence, Maternal Health Investments, and More

This summary of current health news briefs covers polio resurfacing in Gaza, investments in maternal health, and cases of mpox in Pakistan and the Philippines. It also discusses the FDA's tentative approval of Liquidia's inhaled drug, lifting of a partial hold on BioNTech's cancer drug trial, and issues with spice quality in India.

In Gaza, the reemergence of polio has left a mother fearing for her month-old son's health after the first confirmed case in 25 years. In maternal health news, venture capital is flowing into the sector, benefiting providers like doula Kortny Feutardo. In Pakistan, a case of clade 2 mpox has been detected, while the Philippines confirms its first mpox case of the year. In the U.S., the FDA delays traditional approval for Liquidia Corp's inhaled drug, impacting its shares. Meanwhile, BioNTech has received permission to resume trials of its experimental cancer drug. Lastly, nearly 12% of Indian spice samples fail to meet safety standards, prompting regulatory scrutiny.

Ghada al-Ghandour, a resident of Gaza, became concerned for her newborn's health following the confirmation of a polio case by the Palestinian health ministry. On the investment front, the maternal health sector sees significant venture capital interest, aiding providers like Kortny Feutardo who are navigating payment issues with innovative solutions. Mpox, formerly known as monkeypox, has been detected in Pakistan and the Philippines, raising health concerns.

The FDA's hesitance to grant traditional approval for Liquidia Corp's inhaled drug has led to a significant drop in its shares. On a more positive note, BioNTech announces progress in its cancer drug trial following FDA's conditional green light. In India, almost 12% of spice samples have failed quality and safety tests, leading to rigorous checks and regulatory actions.

(With inputs from agencies.)